DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication
Artículo científico (JournalArticle)
Defined spatiotemporal features of RAS-ERK signals dictate cell fate in MCF-7 mammary epithelial cells
Signals conveyed through the RAS-ERK pathway are essential for the determination of cell fate. It is well established that signal variability is achieved in the different microenvironments in which signals unfold. It is also known that signal duration is critical for decisions concerning cell commitment. However, it is unclear how RAS-ERK signals integrate time and space in order to elicit a given biological response. To investigate this, we used MCF-7 cells, in which EGF-induced transient ERK activation triggers proliferation, whereas sustained ERK activation in response to heregulin leads to adipocytic differentiation. We found that both proliferative and differentiating signals emanate exclusively from plasma membrane- disordered microdomains. Of interest, the EGF signal can be transformed into a differentiating stimulus by HRAS overexpression, which prolongs ERK activation, but only if HRAS localizes at disordered membrane. On the other hand, HRAS signals emanating from the Golgi complex induce apoptosis and can prevent heregulin-induced differentiation. Our results indicate that within the same cellular context, RAS can exert different, even antagonistic, effects, depending on its sublocalization. Thus cell destiny is defined by the ability of a stimulus to activate RAS at the appropriate sublocalization for an adequate period while avoiding switching on opposing RAS signals., P.C.’s lab is supported by the Spanish Ministry of Economy–Fondos FEDER (Grant BFU2011-23807) and SAF-2015 63638R (MINECO/FERDER, UE), the Red Temática de Investigación Cooperativa en Cáncer (RD/12/0036/0033), and the Asociación Española Contra el Cáncer (Grant GCB141423113), Spanish Ministry of Health. B.C.
is a Consejo Superior de Investigaciones Científicas JAE-Doc Program Postdoctoral Fellow, supported by the European Social Fund. A.H. has been supported by funding from the European Union Seventh Framework Programme (FP7/2007-2013) PRIMES
project under Grant Agreement FP7-HEALTH-2011-278568., Peer Reviewed